One-year data for HeartFlow’s FFR-CT
One-year data for the FFRCT coronary artery disease algorithm developed by HeartFlow showed that the system reduces the need for invasive treatments and lowers the cost of care.
The 584-patient Platform study compared standard diagnostic strategies to a HeartFlow-guided strategy, using the FFRCT‘s ability to reveal the extent of blockages and their functional impact.
HeartFlow’s FFRCT test uses data from a standard CT scan to create a 3D map of the changes in blood flow as it passes across a coronary lesion.
Among the 60% of patients in the study who had planned invasive coronary angiograms cancelled, none of the 117 subjects suffered an adverse clinical event after 1 year. The HeartFlow system also lowered healthcare costs by 33% at 1 year, compared with standard care (mean costs were 26% after the $1,500 cost of the HeartFlow procedure was factored in, at $9,036 vs. $12,145).
“The Platform trial has demonstrated that the HeartFlow analysis-guided strategy is an effective and proven approach to determine how to optimally manage patients with suspected coronary artery disease – and that the benefits persist over the long term,” chairman & CEO Dr. John Stevens said in prepared remarks. “We have seen a significant increase in the adoption of the HeartFlow analysis in practices around the world, and we believe the clinical and economic advantages demonstrated by this trial will further reinforce that HeartFlow Analysis is an essential technology in the diagnosis and management of cardiovascular disease.” Read more